These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8748624)

  • 1. N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study.
    Traversa R; Pierantozzi M; Semprini R; Loberti M; Cicardi MC; Bassi A; Stanzione P
    J Neural Transm Suppl; 1995; 45():177-85. PubMed ID: 8748624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the amplitude of the N30 frontal component of SEPs during apomorphine test in parkinsonian patients.
    de Mari M; Margari L; Lamberti P; Iliceto G; Ferrari E
    J Neural Transm Suppl; 1995; 45():171-6. PubMed ID: 8748623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Somatosensory evoked potentials and symptomatic response to dopaminergic drugs in Parkinson's disease].
    Castillo JL; Miranda CM; Araya F; Sáez D
    Rev Med Chil; 1996 Mar; 124(3):301-6. PubMed ID: 9008941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormalities of somatosensory evoked potentials in spasmodic torticollis.
    Mazzini L; Zaccala M; Balzarini C
    Mov Disord; 1994 Jul; 9(4):426-30. PubMed ID: 7969209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N30 wave of somatosensory evoked potentials in Parkinson's disease: a pharmacological approach.
    Traversa R; Pierantozzi M; Semprini R; Loberti M; Peppe A; Cicardi MC; Stanzione P
    Electroencephalogr Clin Neurophysiol Suppl; 1996; 46():193-200. PubMed ID: 9059793
    [No Abstract]   [Full Text] [Related]  

  • 6. Median nerve somatosensory evoked potentials. Apomorphine-induced transient potentiation of frontal components in Parkinson's disease and in parkinsonism.
    Rossini PM; Bassetti MA; Pasqualetti P
    Electroencephalogr Clin Neurophysiol; 1995 May; 96(3):236-47. PubMed ID: 7750449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-latency median nerve somatosensory evoked potentials in three cases of parkinsonism and dopa responsive dystonia.
    Margari L; de Mari M; Lamberti P; Iliceto G; Serlenga L; Perniola T; Rossini PM; Ferrari E
    Funct Neurol; 1995; 10(2):99-105. PubMed ID: 7557558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatosensory evoked potentials at rest and during movement in Parkinson's disease: evidence for a specific apomorphine effect on the frontal N30 wave.
    Cheron G; Piette T; Thiriaux A; Jacquy J; Godaux E
    Electroencephalogr Clin Neurophysiol; 1994 Nov; 92(6):491-501. PubMed ID: 7527767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of deep brain stimulation on the frontal N30 component of somatosensory evoked potentials in advanced Parkinson's disease patients.
    Pierantozzi M; Mazzone P; Bassi A; Rossini PM; Peppe A; Altibrandi MG; Stefani A; Bernardi G; Stanzione P
    Clin Neurophysiol; 1999 Oct; 110(10):1700-7. PubMed ID: 10574285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-latency auditory evoked responses in Parkinson disease and in parkinsonism induced by neuroleptics].
    Jacquy J; Mettens P; Blum S; Jacqmotte N; Vanderheyden JE
    Acta Neurol Belg; 1993; 93(3):119-29. PubMed ID: 8102219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease. Clinical and electrophysiological evaluation.
    Al-Bunyan MA
    Saudi Med J; 2000 Jan; 21(1):72-5. PubMed ID: 11533754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients with cervical dystonia after successful treatment with botulinum toxin A.
    Kanovský P; Streitová H; Dufek J; Znojil V; Daniel P; Rektor I
    Mov Disord; 1998 Jan; 13(1):108-17. PubMed ID: 9452335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontal N30 of median nerve SSEPs for evaluation of movement disorders with destructive basal ganglia deficits.
    Fukuda C; Tomita Y; Maegaki Y; Kubota N
    Neuropediatrics; 2003 Aug; 34(4):205-10. PubMed ID: 12973662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curariform peripheral block of muscular tone selectively increases precentral N30 somatosensory evoked potentials component. A pharmacological study carried out on healthy subjects and parkinsonian syndromes.
    Pierantozzi M; Sabato AF; Leonardis F; Marciani MG; Cicardi C; Giacomini P; Bernardi G; Stanzione P
    Exp Brain Res; 2000 Aug; 133(3):368-76. PubMed ID: 10958527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The abnormality of N30 somatosensory evoked potential in idiopathic Parkinson's disease is unrelated to disease stage or clinical scores and insensitive to dopamine manipulations.
    Onofrj M; Fulgente T; Malatesta G; Ferracci F; Thomas A; Curatola L; Bollettini F; Ragno M
    Mov Disord; 1995 Jan; 10(1):71-80. PubMed ID: 7885358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SEPs N30 amplitude in Parkinson's disease and in pharmacologically induced rigidity: relationship with the clinical status.
    Stanzione P; Traversa R; Pierantozzi M; Semprini R; Loberti M; Peppe A; Santilli AM; Bernardi G
    Eur J Neurol; 1997 Jan; 4(1):24-38. PubMed ID: 24283819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parkinson's disease.
    Barboi AC; Goetz CG
    Clin Neuropharmacol; 1999; 22(4):184-91. PubMed ID: 10442246
    [No Abstract]   [Full Text] [Related]  

  • 20. Neurophysiology of sensorimotor integration in Parkinson's disease.
    Rossini PM; Filippi MM; Vernieri F
    Clin Neurosci; 1998; 5(2):121-30. PubMed ID: 10785838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.